Laguna Beach AI Startup Ryght AI Raises $3M Seed and Secures Strategic Investment to Transform Clinical Trials
Ryght AI, a generative and agentic artificial intelligence company focused on transforming clinical research operations, has made notable progress in funding and strategic backing as it scales its technology platform for the life sciences sector. Founded in 2024 and headquartered in Laguna Beach, California, Ryght AI develops an AI‑driven platform aimed at automating clinical trial site selection, activation, feasibility and enrollment through advanced digital twin and generative AI capabilities.
In June 2025, Ryght AI raised $3 million in seed funding, marking a significant early capital infusion to support the expansion of its agentic AI solutions in the clinical research ecosystem. The seed round was led by Foothill Ventures, a venture capital firm focused on early‑stage technology companies, with additional participation from investors including AIX Ventures, Virtue Ventures, IASO Ventures, Top Harvest Capital and Page One Ventures, reflecting a diverse syndicate of backers supporting the company’s mission to streamline and accelerate clinical trial processes.
The funding round underscored investor confidence in Ryght AI’s ability to address long‑standing inefficiencies in drug development, particularly in clinical study site identification and patient recruitment, where traditional methods often slow timelines and increase costs. With this seed capital, the company has worked to expand its engineering team, refine its platform and deepen partnerships within the academic, biotech and pharmaceutical research communities.
Following its seed financing, Ryght AI gained further strategic backing in December 2025, when Accenture Ventures — the investment arm of global professional services firm Accenture — made an undisclosed strategic investment in the company. This investment by Accenture aligns with broader trends of large enterprise technology firms investing in AI startups that offer transformative capabilities for regulated industries such as life sciences, where operational complexity and data challenges are especially pronounced.
Accenture’s investment is designed to support collaborative efforts to accelerate clinical trial feasibility, site selection and patient recruitment by combining Accenture’s industry expertise and data engineering capabilities with Ryght AI’s generative and agentic AI platform. The strategic partnership aims to help sponsors and contract research organizations leverage real‑time insights from digital twin models representing clinical research sites worldwide, optimizing decision‑making and reducing cycle times for trial initiation.
Ryght AI’s platform leverages a secure network of digital twin representations of more than 100,000 clinical trial sites, enabling research sponsors to assess historical performance, patient demographics and operational readiness with greater precision. By integrating advanced AI methods with real‑world operational data, the company’s solutions aim to compress study startup timelines that have traditionally taken months into a matter of weeks, potentially expanding patient access to new therapies while reducing development costs for biotech and pharmaceutical organizations.
The combination of venture capital backing and a strategic investment from a major technology integrator underscores a growing industry focus on AI‑enabled clinical operations, where digital transformation has the potential to improve speed, quality and predictability in research outcomes. Ryght AI’s early funding and subsequent strategic investment suggest that both financial and strategic investors see value in supporting technologies that address bottlenecks across the clinical trial lifecycle.
Ryght AI’s leadership — including CEO Simon Arkell and company co‑founders — have emphasized that the convergence of agentic AI with real‑time data platforms can redefine how clinical trials are designed, launched and managed, helping reduce delays that have long plagued drug development. As the company deploys its solutions more broadly, the funding will continue to fuel growth in partnerships, platform enhancements and market adoption across North America and beyond.
The seed funding and strategic investment milestones mark critical early achievements for Ryght AI as it advances its vision of making clinical research operations more efficient and data‑driven for sponsors, contract research organizations and healthcare innovators alike.
